Name: RELMADA THERAPEUTICS INC (RLMD) Stock
Brand: RELMADA THERAPEUTICS INC
Rating: 5.5 (3 reviews)

RLMD Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Chartmill

Relmada Therapeutics Inc (NASDAQ:RLMD) Reports Wider-Than-Expected Q3 2025 Loss

18 days ago - By: The Motley Fool - Mentions: FDC

Relmada (RLMD) Q3 2025 Earnings Call Transcript

18 days ago - By: Relmada Therapeutics

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

18 days ago - By: Benzinga - Mentions: ECC VINP INV VTGN ...

Earnings Scheduled For November 13, 2025

24 days ago - By: Relmada Therapeutics

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

a month ago - By: Relmada Therapeutics

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Relmada Therapeutics

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

2 months ago - By: Relmada Therapeutics

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

3 months ago - By: Relmada Therapeutics

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

3 months ago - By: Relmada Therapeutics

Relmada Issues Mid-Year CEO Letter to Shareholders

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

4 months ago - By: Relmada Therapeutics

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

6 months ago - By: Relmada Therapeutics

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

7 months ago - By: Relmada Therapeutics

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update